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BACKGROUND & AIMS: Fibrosis affects prognoses for patients with nonalcoholic
fatty liver disease (NAFLD). Several non-invasive scoring systems have aimed to
identify patients at risk for advanced fibrosis, but inconclusive results and variations
in features of patients (diabetes, obesity and older age) reduce their diagnostic
accuracy. We sought to develop a scoring system based on serum markers to
identify patients with NAFLD at risk for advanced fibrosis.
METHODS: We collected data from 2452 patients with NAFLD at medical centers in
Italy, France, Cuba, and China. We developed the Hepamet fibrosis scoring system
using demographic, anthropometric, and laboratory test data, collected at time of
liver biopsy, from a training cohort of patients from Spain (n=768) and validated the
system using patients from Cuba (n=344), Italy (n=288), France (n=830), and China
(n=232). Hepamet fibrosis score (HFS) were compared with those of previously
developed fibrosis scoring systems (the NAFLD fibrosis score [NFS] and FIB-4). The
diagnostic accuracy of the Hepamet fibrosis scoring system was assessed based on
area under the receiver operating characteristic (AUROC) curve, sensitivity,
specificity, diagnostic odds ratio, and positive and negative predictive values and
likelihood ratios.
RESULTS: Variables used to determine HFS were patient sex, age, homeostatic
model assessment score, presence of diabetes, levels of aspartate aminotransferase,
and albumin, and platelet counts; these were independently associated with
advanced fibrosis. HFS discriminated between patients with and without advanced
fibrosis with an AUROC curve value of 0.85 whereas NFS or FIB-4 did so with
AUROC values of 0.80 (P=.0001). In the validation set, cut-off HFS of 0.12 and 0.47
identified patients with and without advanced fibrosis with 97.2% specificity, 74%
sensitivity, a 92% negative predictive value, a 76.3% positive predictive value, a
13.22 positive likelihood ratio, and a 0.31 negative likelihood ratio. HFS were not
affected by patient age, body mass index, hypertransaminasemia, or diabetes. The
Hepamet fibrosis scoring system had the greatest net benefit in identifying patients
who should undergo liver biopsy analysis and led to significant improvements in
reclassification, reducing the number of patients with undetermined results to 20%
from 30% for the FIB-4 and NFS systems (P<.05).
CONCLUSIONS: Using clinical and laboratory data from patients with NAFLD, we
developed and validated the Hepamet fibrosis scoring system, which identified
patients with advanced fibrosis with greater accuracy than the FIB-4 and NFS
systems. the Hepamet system provides a greater net benefit for the decision-making
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